title: Disappearance of B-Symptoms In Comorbid Patients Receiving First-Line Obinutuzumab (Ga101) -Chlorambucil (G-Clb) Or Rituximab-Chlorambucil (R-Clb) for Chronic Lymphocytic Leukemia (Cll).
authors.affiliation: Roche Pharma AG, Grenzach-Wyhlen, Germany.
authors.forename: Andres S
authors.initials: AS
authors.lastname: Wenk
authors.affiliation: F. Hoffmann-La Roche Ltd., Basel, Switzerland.
authors.forename: U
authors.initials: U
authors.lastname: Becker
authors.affiliation: Roche Pharma AG, Grenzach-Wyhlen, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Klawitter
authors.affiliation: Genentech Inc., South San Francisco, CA, USA.
authors.forename: C
authors.initials: C
authors.lastname: Wiesner
authors.affiliation: F. Hoffmann-La Roche Ltd., Basel, Switzerland.
authors.forename: A
authors.initials: A
authors.lastname: Bernhardt